FindTrial
Sign In

i.e.

DRUG3 trials

Sponsors

Biogen Idec Research Limited, Aslan Pharmaceuticals Pte Ltd, Thammasat University

Conditions

Atopic DermatitisRelapsing Forms of Multiple Sclerosismortality in patients with sepsis high central venous oxygen saturation (ScvO2) sepsis mortality oxygen consumption microcirculation

Phase 2

A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis
Active, not recruitingCTIS2022-502552-31-00
Biogen Idec Research LimitedRelapsing Forms of Multiple Sclerosis
Start: 2023-10-03Target: 225Updated: 2025-07-21
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
Not yet recruitingCTIS2023-508329-28-00
Aslan Pharmaceuticals Pte LtdAtopic Dermatitis
Target: 50Updated: 2024-05-31

Unknown Phase

Relationship between high central venous oxygen saturation and mortality in patients with sepsis.
Active, not recruitingTCTR20160314001
Thammasat Universitymortality in patients with sepsis high central venous oxygen saturation (ScvO2) sepsis mortality oxygen consumption microcirculation
Start: 2016-06-02Updated: 2026-03-30